Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Source: SeekingAlpha
2026-02-04 02:09:13 ET
More on Astellas Pharma ADR
- Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
- Seeking Alpha’s Quant Rating on Astellas Pharma ADR
Read the full article on Seeking Alpha
For further details see:
Astellas Pharma ADR GAAP EPS of ¥185.20, revenue of ¥1601.32B; updates full-year forecast
Astellas Pharma Inc
NASDAQ: ALPMF
ALPMF Trading
14.55% G/L:
$16.38 Last:
323 Volume:
$16.38 Open:
ALPMF Latest News
ALPMF Stock Data
$28,999,226,915
1,808,873,137
N/A
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
